Author

Jayne S. Sutherland

Head, TB research - Cited by 5,780 - Immunology - Clinical trials - tuberculosis

Biography

Dr Jayne Sutherland spent her PhD and early post-doctoral career in Australia and London; she changed research objectives from cancer to TB/infectious diseases when she moved to The Gambia in 2006. Jayne also has a background in both murine and clinical immunology, strongly developed during a multi-site sub-Saharan Africa study funded by the Bill and Melinda Gates foundation aimed at determining biomarkers for protective immunity to TB.
Title
Cited by
Year
Four-gene pan-African blood signature predicts progression to tuberculosis
S Suliman, EG Thompson, J Sutherland, J Weiner 3rd, MOC Ota, ...American journal of respiratory and critical care medicine 197 (9), 1198-1208, 2018201
242
2018
Metabolite changes in blood predict the onset of tuberculosis
J Weiner 3rd, J Maertzdorf, JS Sutherland, FJ Duffy, E Thompson, ...Nature communications 9 (1), 5208, 2018201
123
2018
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
A Penn-Nicholson, SK Mbandi, E Thompson, SC Mendelsohn, S Suliman, ...Scientific reports 10 (1), 8629, 2020202
87
2020
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: a prospective cohort study
A Penn-Nicholson, T Hraha, EG Thompson, D Sterling, SK Mbandi, ...PLoS medicine 16 (4), e1002781, 2019201
75
2019
Neutrophils in tuberculosis-associated inflammation and lung pathology
CN Muefong, JS SutherlandFrontiers in immunology 11, 962, 2020202
74
2020
Mitigating the impact of COVID-19 on tuberculosis and HIV services: a cross-sectional survey of 669 health professionals in 64 low and middle-income countries
MS Khan, S Rego, JB Rajal, V Bond, RK Fatima, AK Isani, J Sutherland, ...PloS one 16 (2), e0244936, 2021202
72
2021
A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial
MR Reynolds, JS Allison, A Natale, IL Weisberg, KA Ellenbogen, ...JACC: Clinical Electrophysiology 4 (5), 580-588, 2018201
62
2018
TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB–a study protocol
A Rachow, O Ivanova, R Wallis, S Charalambous, I Jani, N Bhatt, ...BMC pulmonary medicine 19, 1-9, 2019201
49
2019
Complement component C1q as serum biomarker to detect active tuberculosis
R Lubbers, JS Sutherland, D Goletti, RA De Paus, CHM Van Moorsel, ...Frontiers in immunology 9, 2427, 2018201
46
2018
Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results
JS Sutherland, G van der Spuy, A Gindeh, NTT Thuong, AR Namuganga, ...Clinical Infectious Diseases 74 (12), 2136-2141, 2022202
43
2022
Immunometabolic signatures predict risk of progression to active tuberculosis and disease outcome
FJ Duffy, J Weiner III, S Hansen, DL Tabb, S Suliman, E Thompson, ...Frontiers in immunology 10, 527, 2019201
39
2019
Changes in Mycobacterium tuberculosis-Specific Immunity With Influenza co-infection at Time of TB Diagnosis
J Mendy, S Jarju, R Heslop, AL Bojang, B Kampmann, JS SutherlandFrontiers in immunology 9, 93, 2019201
30
2019
Validation and optimization of host immunological bio-signatures for a point-of-care test for TB disease
H Mutavhatsindi, GD Van der Spuy, ST Malherbe, JS Sutherland, A Geluk, ...Frontiers in immunology 12, 607827, 202
21
2021
Delay in the diagnosis of pulmonary tuberculosis in The Gambia, West Africa: A cross-sectional study
OA Owolabi, AO Jallow, M Jallow, G Sowe, R Jallow, MD Genekah, ...International Journal of Infectious Diseases 101, 102-106,
20
2020
Changes in Transcript, Metabolite, and Antibody Reactivity During the Early Protective Immune Response in Humans to Mycobacterium tuberculosis Infection
J Weiner, T Domaszewska, S Donkor, SHE Kaufmann, PC Hill, ...Clinical infectious diseases 71 (1), 30-40, 2020202
17
2020
Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers
MA Vickers, F Darboe, CN Muefong, G Mbayo, A Barry, A Gindeh, S Njie, ...Frontiers in immunology 11, 572620, 2020202
14
2020
Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients
R Lubbers, JS Sutherland, D Goletti, RA De Paus, DJ Dijkstra, ...Molecular immunology 120, 187-195, 2020202
13
2020
Neutrophils contribute to severity of tuberculosis pathology and recovery from lung damage pre-and posttreatment
C Nwongbouwoh Muefong, O Owolabi, S Donkor, S Charalambous, ...Clinical Infectious Diseases 74 (10), 1757-1766, 2022202
9
2022
Analysis of cellular and soluble profiles in QuantiFERON nonconverters, converters, and reverters in the Gambia
L Medawar, HM Tukiman, G Mbayo, S Donkor, O Owolabi, JS SutherlandImmunity, inflammation and disease 7 (4), 260-270, 2019201
8
2019
Major neutrophil-derived soluble mediators associate with baseline lung pathology and post-treatment recovery in tuberculosis patients
CN Muefong, O Owolabi, S Donkor, S Charalambous, J Mendy, I Sey, ...Frontiers in Immunology 12, 40933, 2021202
7
2021

Referred From: https://scholar.google.com/citations?hl=en&user=7qtMknYAAAAJ

Cited by
Citations 5780
h-index 41
i10-index 67
Recommended Journals
Open Access Journals